🕵️ Avalo Therapeutics, Inc. ($AVTX)
SEC insider & ownership activity, last 12 months · CIK 1534120 · every row links its SEC filing
Over the last 12 months insiders sold $6.6M with no open-market buying against it. Doyle Mittie sold $2.9M through a 10b5-1 trading plan in 14 lots (Mar–Jul). 2 planned sales are pending, the largest $764K (Christopher Sullivan). No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
0 buyers, $0 (0 lots) · 5 sellers, $6.6M (34 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Doyle Mittie | 0 | – | 14 | $2.9M | Jul 27, 2026 |
| Sullivan Christopher Ryan | 0 | – | 12 | $1.9M | May 7, 2026 |
| Varki Paul | 0 | – | 5 | $1.5M | May 6, 2026 |
| Jonathan Goldman | 0 | – | 2 | $163K | Nov 14, 2025 |
| Mitchell Chan | 0 | – | 1 | $72K | May 6, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| BVF Partners L P/IL | 10.0% | 13G | May 15, 2026 | filing ↗ | |
| BVF INC/IL | 10.0% | 13G | May 15, 2026 | filing ↗ | |
| Mark N. Lampert | 10.0% | 13G | May 15, 2026 | filing ↗ | |
| Commodore Capital LP | 9.9% | 13G | Jun 18, 2026 | filing ↗ | |
| Commodore Capital Master LP | 9.9% | 13G | Jun 18, 2026 | filing ↗ | |
| Robert Egen Atkinson | 9.9% | 13G | Jun 18, 2026 | filing ↗ | |
| Michael Kramarz | 9.9% | 13G | Jun 18, 2026 | filing ↗ | |
| RA Capital Management, L.P. | 9.9% | 13G | May 15, 2026 | filing ↗ | |
| Peter Kolchinsky | 9.9% | 13G | May 15, 2026 | filing ↗ | |
| Rajeev Shah | 9.9% | 13G | May 15, 2026 | filing ↗ | |
| RA Capital Healthcare Fund, L.P. | 9.9% | 13G | May 15, 2026 | filing ↗ | |
| T. ROWE Price Investment Management, Inc. | 9.5% | 13G | May 15, 2026 | filing ↗ | |
| Nantahala Capital Management, LLC | 9.4% | 13G | Nov 14, 2025 | filing ↗ | |
| Wilmot B. Harkey | 9.4% | 13G | Nov 14, 2025 | filing ↗ | |
| Daniel Mack | 9.4% | 13G | Nov 14, 2025 | filing ↗ | |
| BVF GP Holdings LLC | 9.3% | 13G | May 15, 2026 | filing ↗ | |
| TCG Crossover GP II, LLC | 7.9% | 13G | May 12, 2026 | filing ↗ | |
| TCG Crossover Fund II, L.P. | 7.9% | 13G | May 12, 2026 | filing ↗ | |
| Chen Yu | 7.9% | 13G | May 12, 2026 | filing ↗ | |
| Affinity Healthcare Fund, LP | 7.7% | 13G | Nov 13, 2025 | filing ↗ | |
| Caligan Partners LP | 7.2% | 13G | May 15, 2026 | filing ↗ | |
| David Johnson | 7.2% | 13G | May 15, 2026 | filing ↗ | |
| Blackrock, Inc. | 6.5% | 13G | Jul 27, 2026 | filing ↗ | |
| FMR LLC | 6.1% | 13G | Jun 5, 2026 | filing ↗ | |
| Abigail P. Johnson | 6.1% | 13G | Jun 5, 2026 | filing ↗ | |
| Orbimed Capital GP IX LLC | 6.0% | 13G | Aug 14, 2025 | filing ↗ | |
| DEEP Track Capital, LP | 5.8% | 13G | May 29, 2026 | filing ↗ | |
| DEEP Track Biotechnology Master Fund, Ltd. | 5.8% | 13G | May 29, 2026 | filing ↗ | |
| David Kroin | 5.8% | 13G | May 29, 2026 | filing ↗ | |
| Avoro Capital Advisors LLC | 5.8% | 13G | May 15, 2026 | filing ↗ | |
| Behzad Aghazadeh | 5.8% | 13G | May 15, 2026 | filing ↗ | |
| Affinity Asset Advisors, LLC | 5.5% | 13G | May 14, 2026 | filing ↗ | |
| Michael Cho | 5.5% | 13G | May 14, 2026 | filing ↗ | |
| Biotechnology Value Fund L P | 5.4% | 13G | May 15, 2026 | filing ↗ | |
| BVF I GP LLC | 5.4% | 13G | May 15, 2026 | filing ↗ | |
| Affinity Healthcare Fund, LP | 5.3% | 13G | Dec 31, 2024 | filing ↗ | |
| Affinity Asset Advisors, LLC | 5.3% | 13G | Dec 31, 2024 | filing ↗ | |
| POINT72 Asset Management, L.P. | 5.2% | 13G | May 26, 2026 | filing ↗ | |
| POINT72 Capital Advisors, Inc. | 5.2% | 13G | May 26, 2026 | filing ↗ | |
| Steven A. Cohen | 5.2% | 13G | May 26, 2026 | filing ↗ | |
| Millennium Management LLC | exited | 13G | Jul 6, 2026 | filing ↗ | |
| Millennium Group Management LLC | exited | 13G | Jul 6, 2026 | filing ↗ | |
| Israel A. Englander | exited | 13G | Jul 6, 2026 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Jonathan Goldman | $616K | Jun 2, 2026 | filing ↗ |
| Christopher Sullivan | $406K | May 7, 2026 | filing ↗ |
| Mittie Doyle | $886K | May 6, 2026 | filing ↗ |
| Christopher Sullivan | $764K | May 6, 2026 | filing ↗ |
| Paul Varki | $1.5M | May 6, 2026 | filing ↗ |
| Mitchell Chan | $51K | May 6, 2026 | filing ↗ |
| Christopher Sullivan | $218K | Apr 29, 2026 | filing ↗ |
| Mittie Doyle | $1.2M | Apr 6, 2026 | filing ↗ |
| Christopher Sullivan | $238K | Apr 1, 2026 | filing ↗ |
| Mittie Doyle | $467K | Mar 16, 2026 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Officer/director changes (5.02) | Jun 23, 2026 | filing ↗ |
| Other events (8.01) | Jun 16, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 16, 2026 | filing ↗ |
| Unregistered equity sale (3.02) | Jun 11, 2026 | filing ↗ |
| Material Modifications to Rights of Security Holders (3.03) | Jun 11, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jun 11, 2026 | filing ↗ |
| Charter/bylaw changes (5.03) | Jun 11, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 11, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jun 2, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 2, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 2, 2026 | filing ↗ |
| Earnings (2.02) | May 13, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 13, 2026 | filing ↗ |
| Other events (8.01) | May 5, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 5, 2026 | filing ↗ |
| Material agreement (1.01) | May 5, 2026 | filing ↗ |
| Earnings (2.02) | May 5, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | May 5, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 5, 2026 | filing ↗ |
| Material agreement (1.01) | Apr 26, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Apr 26, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 26, 2026 | filing ↗ |
| Officer/director changes (5.02) | Mar 23, 2026 | filing ↗ |
| Earnings (2.02) | Mar 23, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 23, 2026 | filing ↗ |
| Earnings (2.02) | Jan 12, 2026 | filing ↗ |
| Other events (8.01) | Jan 12, 2026 | filing ↗ |
| Other events (8.01) | Dec 2, 2025 | filing ↗ |
| Earnings (2.02) | Nov 6, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 6, 2025 | filing ↗ |